tiprankstipranks
Advertisement
Advertisement
Can-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
PremiumCompany AnnouncementsCan-Fite to Advance Namodenoson into Phase 2b Pancreatic Cancer Combo Trial After Positive Data
23d ago
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
Premium
The Fly
Can-Fite BioPharma target adjusted to $5 from $2.50 at H.C. Wainwright
24d ago
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
Premium
Company Announcements
Can-Fite Posts Positive Phase 2a Results for Namodenoson in Advanced Pancreatic Cancer
1M ago
Can-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
PremiumCompany AnnouncementsCan-Fite BioPharma Posts 2025 Loss but Highlights Long-Term Cancer Survival and Clinical Progress
2M ago
CANF Upcoming Earnings Report: What to Expect?
Premium
Pre-Earnings
CANF Upcoming Earnings Report: What to Expect?
2M ago
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
Premium
Company Announcements
Can-Fite Secures Israeli Patent to Bolster Namodenoson Anti-Obesity Franchise
3M ago
Can-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
PremiumThe FlyCan-Fite BioPharma says namodenoson meets primary endpoint in Phase 2a study
3M ago
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
Premium
Company Announcements
Can-Fite BioPharma Adjourns Special Shareholders’ Meeting to March 10, 2026
3M ago
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
Premium
Company Announcements
Can-Fite Targets Rare Kidney Disease With New Phase 2 Lowe Syndrome Trial
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100